SCHEMBL10101575

SCHEMBL10101575

C[C@H]1[C@H](O)[C@H](c2cc(C(=O)O)c3c(N)ncnn23)O[C@@H]1CO

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CSNK2A2 P19784 5/20 0.34
▸ CSNK2A1 P68400 5/20 0.34
▸ ACVRL1 P37023 3/20 0.34
▸ ADORA3 P0DMS8 3/20 0.33
▸ DPP4 P27487 1/20 0.33
▸ NTRK1 P04629 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ SLC28A1 O00337 1/20 0.33
▸ MAP3K7 O43318 1/20 0.33
▸ SLC28A2 O43868 1/20 0.33
▸ GAPDH P04406 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ ADORA2A P29274 1/20 0.33
▸ ADORA2B P29275 1/20 0.33
▸ ADORA1 P30542 1/20 0.33
▸ STAT6 P42226 1/20 0.33
▸ PI4KA P42356 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ PI4K2B Q8TCG2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10101578 0.92 KDM4E (0.36) CSNK2A2CSNK2A1ACVRL1ADORA3DPP4
SCHEMBL10100350 0.91 HIF1A (0.41) ACVRL1ADORA3DPP4MEN1SLC28A1
SCHEMBL10101513 0.89 CSNK2A2 (0.34) CSNK2A2CSNK2A1ACVRL1NTRK1AXL
SCHEMBL10101576 0.89 CSNK2A2 (0.34) CSNK2A2CSNK2A1ACVRL1NTRK1AXL
SCHEMBL10101583 0.88 NPC1 (0.40) CSNK2A2CSNK2A1ACVRL1ADORA3DPP4
SCHEMBL13519789 0.86 LGALS3 (0.35) ACVRL1ADORA3DPP4MEN1SLC28A1
SCHEMBL10101568 0.84 PIK3CD (0.36) ACVRL1ADORA3DPP4MEN1SLC28A1
SCHEMBL10101558 0.84 ADK (0.35) ACVRL1ADORA3DPP4MEN1SLC28A1
SCHEMBL10101562 0.84 ACVRL1 (0.40) ACVRL1ADORA3DPP4MEN1SLC28A1
SCHEMBL10101588 0.82 HIF1A (0.35) ACVRL1ADORA3DPP4MEN1SLC28A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119607-B2 Bicyclic nucleosides and nucleotides as therapeutic agents BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2012-02-21 — — US disclosed
US-20100035836-A1 BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS BIOTA SCIENTIFIC MANAGEMENT (AU) 2010-02-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035836-A1 BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS NTPCR, PNP, DCTD CSNK2A2 4716/4885CSNK2A1 4695/4885ACVRL1 4215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback